Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Minoryx Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Interphex Week Tokyo

              Participation Not Confirmed

              Update your events

              EIB Provides Minoryx with up to €25 Million to Support Development of Breakthrough Therapies in Orphan Neurodegenerative Diseases

              Contact the Supplier

              Lead Product(s): Leriglitazone

              Therapeutic Area: Genetic Disease Product Name: MIN-102

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: European Investment Bank

              Deal Size: $29.0 million Upfront Cash: Undisclosed

              Deal Type: Funding October 30, 2020

              Details:

              The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.

              Minoryx Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Interphex Week Tokyo

              Participation Not Confirmed

              Update your events

              Minoryx Therapeutics and Sperogenix Therapeutics Sign License Pact to Develop and Commercialize Leriglitazone in Mainland China

              Contact the Supplier

              Lead Product(s): Leriglitazone

              Therapeutic Area: Genetic Disease Product Name: MIN-102

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sperogenix Therapeutics

              Deal Size: $78.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 23, 2020

              Details:

              Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.

              PharmaCompass__DigitalAd